Related references
Note: Only part of the references are listed.Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase
O. Shpilberg et al.
BRITISH JOURNAL OF CANCER (2013)
Comparative pharmacokinetics of subcutaneous trastuzumab administered via handheld syringe or proprietary single-use injection device in healthy males
Chris J. Wynne et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2-Positive Breast Cancer
Chris Wynne et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study
Xavier Pivot et al.
LANCET ONCOLOGY (2013)
Development of a Subcutaneous Formulation for Trastuzumab - Nonclinical and Clinical Bridging Approach to the Approved Intravenous Dosing Regimen
B. Bittner et al.
ARZNEIMITTELFORSCHUNG-DRUG RESEARCH (2012)
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial
Gustavo Ismael et al.
LANCET ONCOLOGY (2012)
POTENTIAL TIME SAVINGS WITH TRASTUZUMAB SUBCUTANEOUS (SC) INJECTION VERSUS TRASTUZUMAB INTRAVENOUS (IV) INFUSION: RESULTS FROM INTERVIEWS CONDUCTED AS PART OF A TIME-AND-MOTION STUDY (T&M) ACROSS 17 SITES
E. De Cock et al.
VALUE IN HEALTH (2012)
POTENTIAL TIME AND COST SAVINGS WITH HERCEPTIN (TRASTUZUMAB) SUBCUTANEOUS (SC) INJECTION VERSUS HERCEPTIN INTRAVENOUS (IV) INFUSION: RESULTS FROM THREE DIFFERENT ENGLISH PATIENT SETTINGS
K. Samanta et al.
VALUE IN HEALTH (2012)
Trastuzumab A Review of its Use as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer
Karly P. Garnock-Jones et al.
DRUGS (2010)
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Clifford A. Hudis
NEW ENGLAND JOURNAL OF MEDICINE (2007)
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Ian Smith et al.
LANCET (2007)
Trastuzumab - A review of its use in the treatment of metastatic breast cancer overexpressing HER2
K McKeage et al.
DRUGS (2002)
Share Paper
